All Articles

Immersion's revenue soars post-BNED deal, but profits plummet. Can a haptics innovator thrive while managing an education giant and keep investors happy?

A 30% profit drop at Ohio Valley Banc Corp. highlights a risky strategy: funding rapid loan growth with costly deposits as major credit issues emerge.

FDA clears a pivotal study for Medicus Pharma's SkinJect, a microneedle patch offering new hope for Gorlin Syndrome and a new playbook in biotech strategy.

A Crown corporation's new flyer service is gutting community newspapers, sparking a crisis that pits public service against profit and threatens local democracy.

Rosenberg & Parker's new Financial Institutions Practice, led by Nathan Hummel, signals a major shift in how banks manage risk and capital.

Small biotech Veru Inc. is betting its future on improving blockbuster weight-loss drugs, targeting the hidden cost of muscle loss in a billion-dollar market.

A novel partnership aims to create the first drug for ReNU syndrome, a condition found in 2024, potentially redefining rare disease drug development.

DBGI announced a massive program expansion, but a recent stock split, weak financials, and a fight against market anomalies paint a complex picture.

Catalogic's latest DPX release adds agentless Proxmox protection and deepens cyber resilience, a strategic move to unify data management in a fragmenting IT world.

Pacira BioSciences de-risks its promising knee osteoarthritis gene therapy by solving the manufacturing puzzle, a key step from lab to market for millions.

Paragon Bank's dividend signals more than financial health; it's the result of a unique growth model fueled by an award-winning culture. Here's how.

AsymBio breaks ground on a Shanghai R&D center, integrating AI and manufacturing to slash drug development timelines. Is this the end of the CDMO handoff?

Slovakian battery innovator InoBat is going public via a SPAC deal, aiming its advanced energy storage at the insatiable power demands of AI and data centers.

As the U.S. is poised to become the world's top olive oil consumer, Spain launches a massive campaign to move its liquid gold from commodity to icon.

A strategic investment in RH Aero Systems by Capitol Meridian Partners isn't just a deal; it's a move to fortify the critical, unseen infrastructure of global flight.

The appointment of M&A expert La Vonda Williams to a strategic review committee isn't just a personnel change; it's a clear signal to Wall Street.

With its transformation to a pure-play tech firm complete, Altus Group brings in a new CFO to hit aggressive growth targets and harness the power of AI.

Veteran strategist Rashad Robinson's new book offers a tactical guide for moving beyond protest to dismantle consolidated corporate and tech power.

With a new CMO and fresh funding, Spero Therapeutics is betting big on its immunology asset SP001. Can Dr. Zack guide it to success in a competitive field?